MR CLEAN LATE
Endovascular Treatment of Acute Stroke for Late arrivals.
This website provides information about the MR CLEAN LATE trial, a multicenter randomized clinical performed within the CONTRAST consortium. The goal is to assess the effect of endovascular treatment, compared with best medical treatment, in patients with acute ischemic stroke presenting between 6 and 24 hours after onset (or last seen well) caused by an intracranial large vessel occlusion of the anterior circulation.
In the menu on the left side of this website you will find links to the patient information forms (PIF), the case report form (CRF) and to the randomization site.
MR CLEAN LATE principal investigators on behalf of the CONTRAST consortium.
Robert van Oostenbrugge and Wim van Zwam
Maastricht University Medical Center, Maastricht
Final patient included in the MR CLEAN LATE
On the 27th of January 2022, the final patient (with registered consent) was included in the MR CLEAN LATE trial.
Since a few consents were still “pending” at the time, we expect the final MR CLEAN LATE study population to contain 501-502 subjects.
Furthermore, we aim to present our first results at the World stroke Congress in October this year.
Robert van Oostenbrugge & Wim van Zwam
Maastricht University Medical Center+, Maastricht